Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands:: Temporal trends and evidence for vaccine-driven evolution

被引:254
|
作者
Mooi, FR
van Oirschot, H
Heuvelman, K
van der Heide, HGJ
Gaastra, W
Willems, RJL
机构
[1] Natl Inst Publ Hlth & Environm, Res Lab Infect Dis, NL-3720 BA Bilthoven, Netherlands
[2] Univ Utrecht, Inst Infect Dis & Immunol, Fac Vet Med, NL-3508 TD Utrecht, Netherlands
关键词
D O I
10.1128/IAI.66.2.670-675.1998
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Bordetella pertussis proteins P.69 (also designated pertactin) and pertussis toxin are important virulence factors and have been shown to confer protective immunity in animals and humans, Both proteins are used in the new generation of acellular pertussis vaccines (ACVs), and it is therefore important to study the degree of antigenic variation in these proteins, Sequence analysis of the genes for P.69 and the pertussis toxin SI subunit, using strains collected from Dutch patients in the period 1949 to 1996, revealed three P.69 and three S1 variants which show differences in amino acid sequence, Polymorphism in P.69 was confined to a region comprised of repeats and located proximal to the RGD motif involved in adherence to host tissues, Variation in S1 was observed in two regions previously identified as T-cell epitopes, P.69 and S1 variants, identical to those included in the Dutch whole-cell pertussis vaccine (WCV), were found in 100% of the strains from the 1950s, the period when the WCV was introduced in The Netherlands, However, nonvaccine types of P.69 and S1 gradually replaced the vaccine types in later years and were found in similar to 90% strains from 1990 to 1996, These results suggest that vaccination has selected for strains which are antigenically distinct from vaccine strains. Analysis of strains from vaccinated and nonvaccinated individuals indicated that the WCV protects better against strains with the vaccine type P.69 than against strains with non-vaccine types (P = 0.024), ACVs contain P.69 and S1 types which are found in only 10% of recent Dutch B. pertussis isolates, implying that they do not have an optimal composition, Our findings cast a new light on the reemergence of pertussis in highly vaccinated populations and may have major implications for the long-term efficacy of both WCVs and ACVs.
引用
收藏
页码:670 / 675
页数:6
相关论文
共 21 条
  • [1] Structure of Bordetella pertussis virulence factor P.69 pertactin
    Emsley, P
    Charles, IG
    Fairweather, NF
    Isaacs, NW
    NATURE, 1996, 381 (6577) : 90 - 92
  • [2] Pertactin Deficient Bordetella pertussis, Vaccine-Driven Evolution and Reemergence of Pertussis
    Ma, Longhuan
    Caulfield, Amanda
    Dewan, Kalyan K.
    Harvill, Eric T.
    EMERGING INFECTIOUS DISEASES, 2021, 27 (06) : 1561 - 1566
  • [3] Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells
    Everest, P
    Li, JL
    Douce, G
    Charles, I
    DeAzavedo, J
    Chatfield, S
    Dougan, G
    Roberts, M
    MICROBIOLOGY-SGM, 1996, 142 : 3261 - 3268
  • [4] Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999
    Cassiday, P
    Sanden, G
    Heuvelman, K
    Mooi, F
    Bisgard, KM
    Popovic, T
    JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05): : 1402 - 1408
  • [5] Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland
    Mooi, FR
    He, QS
    van Oirschot, H
    Mertsola, J
    INFECTION AND IMMUNITY, 1999, 67 (06) : 3133 - 3134
  • [6] The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition
    Hijnen, Marcel
    de Voer, Richarda
    Mooi, Frits R.
    Schepp, Rutger
    Moret, Ed E.
    van Gageldonk, Pieter
    Smits, Gaby
    Berbers, Guy A. M.
    VACCINE, 2007, 25 (31) : 5902 - 5914
  • [7] Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen
    Hijnen, M
    Mooi, FR
    van Gageldonk, PGM
    Hoogerhout, P
    King, AJ
    Berbers, GAM
    INFECTION AND IMMUNITY, 2004, 72 (07) : 3716 - 3723
  • [8] The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli
    Hijnen, M
    van Gageldonk, PGM
    Berbers, GAM
    van Woerkom, T
    Mooi, FR
    PROTEIN EXPRESSION AND PURIFICATION, 2005, 41 (01) : 106 - 112
  • [9] Insight into Evolution of Bordetella pertussis from Comparative Genomic Analysis: Evidence of Vaccine-Driven Selection
    Octavia, Sophie
    Maharjan, Ram P.
    Sintchenko, Vitali
    Stevenson, Gordon
    Reeves, Peter R.
    Gilbert, Gwendolyn L.
    Lan, Ruiting
    MOLECULAR BIOLOGY AND EVOLUTION, 2011, 28 (01) : 707 - 715
  • [10] Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom
    Fry, NK
    Neal, S
    Harrison, TG
    Miller, E
    Matthews, R
    George, RC
    INFECTION AND IMMUNITY, 2001, 69 (09) : 5520 - 5528